Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: RECEPTOR, ERBB-2 - GENETICS , . Treffer: 19

2019

Filipits, M; Dubsky, P; Rudas, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, CF; Hlauschek, D; Brown, K; Bernhisel, R; Kronenwett, R; Lancaster, JM; Fitzal, F; Gnant, M Prediction of Distant Recurrence Using EndoPredict Among Women with ER⁺, HER2^- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
Clin Cancer Res. 2019; 25(13):3865-3872 Doi: 10.1158/1078-0432.CCR-19-0376 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gnant, M; Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Jakesz, R; Marth, C; Sevelda, P; Mlineritsch, B; Exner, R; Fesl, C; Frantal, S; Singer, CF, , Austrian, Breast, and, Colorectal, Cancer, Study, Group Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2019; 20(3):339-351 Doi: 10.1016/S1470-2045(18)30862-3
Web of Science PubMed FullText FullText_MUG

 

2017

Loibner, M; Oberauner-Wappis, L; Viertler, C; Groelz, D; Zatloukal, K Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation.
J Vis Exp. 2017; 8(130): Doi: 10.3791/55885 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Singer, CF; Tan, YY; Fitzal, F; Steger, GG; Egle, D; Reiner, A; Rudas, M; Moinfar, F; Gruber, C; Petru, E; Bartsch, R; Tendl, KA; Fuchs, D; Seifert, M; Exner, R; Balic, M; Bago-Horvath, Z; Filipits, M; Gnant, M; Austrian Breast and Colorectal Cancer Study Group Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Clin Cancer Res. 2017; 23(14):3676-3683 Doi: 10.1158/1078-0432.CCR-16-2373 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Jueckstock, J; Rack, B; Friedl, TW; Scholz, C; Steidl, J; Trapp, E; Tesch, H; Forstbauer, H; Lorenz, R; Rezai, M; Häberle, L; Alunni-Fabbroni, M; Schneeweiss, A; Beckmann, MW; Lichtenegger, W; Fasching, PA; Pantel, K; Janni, W; SUCCESS Study Group Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
BMC Cancer. 2016; 16(10):401-401 Doi: 10.1186/s12885-016-2454-3 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Oberauner-Wappis, L; Loibner, M; Viertler, C; Groelz, D; Wyrich, R; Zatloukal, K Protocol for HER2 FISH determination on PAXgene-fixed and paraffin-embedded tissue in breast cancer.
Int J Exp Pathol. 2016; 97(2):202-206 Doi: 10.1111/iep.12185 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Schramm, A; Friedl, TW; Schochter, F; Scholz, C; de Gregorio, N; Huober, J; Rack, B; Trapp, E; Alunni-Fabbroni, M; Müller, V; Schneeweiss, A; Pantel, K; Meier-Stiegen, F; Hartkopf, A; Taran, FA; Wallwiener, D; Janni, W; Fehm, T Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Arch Gynecol Obstet. 2016; 293(2):271-281 Doi: 10.1007/s00404-015-3879-7
Web of Science PubMed FullText FullText_MUG

 

Sysa-Shah, P; Tocchetti, CG; Gupta, M; Rainer, PP; Shen, X; Kang, BH; Belmonte, F; Li, J; Xu, Y; Guo, X; Bedja, D; Gao, WD; Paolocci, N; Rath, R; Sawyer, DB; Naga Prasad, SV; Gabrielson, K Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.
Cardiovasc Res. 2016; 109(3):358-373 Doi: 10.1093/cvr/cvv274 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Benhaim, L; Zhang, W; Wakatsuki, T; Yang, D; Gerger, A; Bohanes, P; Paez, D; Loupakis, F; LaBonte, MJ; Ning, Y; El-Khoueiry, R; Ladner, R; Wilson, P; Zhang, H; Giamas, G; Stebbing, J; Lenz, HJ Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.
Pharmacogenomics J. 2015; 15(3):235-240 Doi: 10.1038/tpj.2014.58
Web of Science PubMed FullText FullText_MUG

 

Fitzal, F; Filipits, M; Rudas, M; Greil, R; Dietze, O; Samonigg, H; Lax, S; Herz, W; Dubsky, P; Bartsch, R; Kronenwett, R; Gnant, M The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
Br J Cancer. 2015; 112(8):1405-1410 Doi: 10.1038/bjc.2015.98 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Jahn, SW; Kashofer, K; Halbwedl, I; Winter, G; El-Shabrawi-Caelen, L; Mentzel, T; Hoefler, G; Liegl-Atzwanger, B Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
Mod Pathol. 2015; 28(7):895-903 Doi: 10.1038/modpathol.2015.39 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Aigner, B; Plötz, SG; Schaller, G Triple-negative breast cancer possibly transforming into malignant melanoma due to targeted therapy? A case report and review of literature.
Wien Med Wochenschr. 2013; 163(21-22): 495-498. Doi: 10.1007/s10354-013-0242-0 (- Case Report)
PubMed FullText FullText_MUG

 

Stöger, H Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].
Dtsch Med Wochenschr. 2013; 138(41):2096-2096 Doi: 10.1055/s-0033-1349531
Web of Science PubMed FullText FullText_MUG

 

2011

Kap, M; Smedts, F; Oosterhuis, W; Winther, R; Christensen, N; Reischauer, B; Viertler, C; Groelz, D; Becker, KF; Zatloukal, K; Langer, R; Slotta-Huspenina, J; Bodo, K; de Jong, B; Oelmuller, U; Riegman, P Histological assessment of PAXgene tissue fixation and stabilization reagents.
PLOS ONE. 2011; 6(11): e27704-e27704. Doi: 10.1371/journal.pone.0027704 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2009

Kramer, A; Gattenlohner, S; Neben, K CUP syndrome: molecular pathogenesis and biology
Pathologe. 2009; 30(2):117-124 Doi: 10.1007/s00292-008-1114-z
Web of Science PubMed FullText FullText_MUG

 

2008

Peintinger, F; Buzdar, AU; Kuerer, HM; Mejia, JA; Hatzis, C; Gonzalez-Angulo, AM; Pusztai, L; Esteva, FJ; Dawood, SS; Green, MC; Hortobagyi, GN; Symmans, WF Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Ann Oncol. 2008; 19(12): 2020-2025. Doi: 10.1093/annonc/mdn427 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2004

Krippl, P; Langsenlehner, U; Samonigg, H; Renner, W; Köppel, H Vascular endothelial growth factor in predicting outcome in breast cancer.
CLIN CANCER RES 2004 10: 8752-8753. Doi: 10.1158/1078-0432.CCR-04-1211 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2003

Jelincic, D; Hudelist, G; Singer, CF; Bauer, M; Horn, LC; Bilek, K; Czerwenka, K Clinicopathologic profile of gestational trophoblastic disease.
Wien Klin Wochenschr. 2003; 115(1-2):29-35 Doi: 10.1007/BF03040269
Web of Science PubMed FullText FullText_MUG

 

1995

Stühlinger, M; Rosen, AC; Dobianer, K; Hruza, C; Helmer, H; Kein, M; Koukal, T; Reiner, A; Klein, M; Spona, J HER-2 oncogene is not amplified in primary carcinoma of the fallopian tube. Austrian Cooperative Study Group for Fallopian Tube Carcinoma.
Oncology. 1995; 52(5):397-399 Doi: 10.1159/000227496
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum